Modified Head and Neck Swallow Scale: Using EORTC-QLQ-H&N35 to Predict Overall Survival.
Modified Head and Neck Swallow Scale: Using EORTC-QLQ-H&N35 to Predict Overall Survival.
复制标题
改良头颈吞咽量表:使用 EORTC-QLQ-H
DOI:
10.1002/lary.29559
复制
发表时间:
2021
期刊:
影响因子:
--
通讯作者:
Howell,RebeccaJ
中科院分区:
文献类型:
--
作者:
vonAllmen,Douglas;Tang,Alice;Takiar,Vinita;Zender,Chad;Romeo,Stephen;Masch,Jessica;Casper,Keith;Patil,Yash;Wilson,Keith;Khosla,Siddarth;Niu,Liang;Altaye,Mekibib;Tabangin,Meredith;Howell,RebeccaJ
Objectives/HypothesisDysphagia is a treatment‐related complication of head and neck cancer (HNCA). We demonstrate the predictive value of a modified head and neck swallow scale (m‐HNSW) adapted from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire‐Head and Neck 35 (EORTC‐QLQ‐H&N35).Study DesignRetrospective Cohort Study.MethodsRetrospective, single‐center cohort study utilizing a prospectively collected database of HNCA patients in a high‐volume tertiary referral center. 736 HNCA patients more than 2 years from completion of treatment were identified. EORTC‐QLQ‐H&N35 data collected from at least one of three defined episodes of care were used. The m‐HNSW uses three questions to form a 9‐point dysphagia scale. A Cox proportional hazards model was used to determine the effect of the m‐HNSW while controlling for demographics, tumor staging, site, and treatment.ResultsUsing data from 3, 6, 12 months from treatment, we analyzed a subset that included 328 patients. Three months after the completion of therapy, the m‐HNSW score had a significant association with 1 (HR = 1.24,P= .0005) and 5 year survival (HR = 1.19,P= .0002) after accounting for body mass index. Six (HR = 1.14,P= .014) and 12 month (hazard ratio (HR) = 1.33,P< .0001) scores post completion of therapy predict 5‐year survival. An increase of the m‐HNSW score by 1 point was associated with an increase in death by 24%, and 19% at 1 and 5 years following therapy.ConclusionsThe m‐HNSW is a simple assessment of dysphagia using previously validated EORTC‐QLC‐H&N35 data that when taken at 3, 6, and 12 months after completion of therapy is predictive of overall survival.Level of Evidence4Laryngoscope, 131:2478–2482, 2021